NCT07023315View on ClinicalTrials.gov

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

760

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2031

Conditions
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
DRUG

Cadonilimab

Anti-PD-1/ CTLA-4 tetrameric bispecific antibody

DRUG

SOX chemotherapy

A combination treatment made up of oxaliplatin and tegafur-gimeracil-oteracil potassium

Trial Locations (6)

100143

Peking University Cancer Hospital, Beijing

Unknown

Fujian Provincial Cancer Hospital, Fuzhou

Fourth Hospital of Hebei Medical University, Shijiazhuang

Harbin Medical University Cancer Hospital, Harbin

Zhongshan Hospital, Fudan University, Shanghai

Tianjin Provincial Tumor Hospital, Tianjin

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT07023315 - A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma | Biotech Hunter | Biotech Hunter